MKI67 and glioblastoma: The results of immunohistochemistry showed that the positive rate of Ki67 cells was significantly reduced after AZD-9291 and GDC-0084 combination therapy (Fig. 5J), further confirming that the combination therapy significantly inhibited the growth of GBM cells in vivo and prolonged the survival of tumor-bearing mice.